Trial
NCT04430036
AGEN1884 Plus AGEN2034 Combined With Cisplatin-Gemcitabine for Muscle-Invasive Bladder Cancer
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
The University of Texas Health Science Center at San Antonio
Collaborators
—
Condition
Urinary Bladder Neoplasms
Intervention
AGEN1884
Why stopped
PI left the institution
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-04-04